MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 526210 | Name: Ro 41-5253
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Ro 41-5253 is a selective RARα antagonist. Ro 41-5253 suppresses retinoic acid-induced connexin 43 protein expression in 10T1/2 cells.

Chemical Structure

Ro 41-5253
Ro 41-5253
CAS#144092-31-9

Theoretical Analysis

MedKoo Cat#: 526210

Name: Ro 41-5253

CAS#: 144092-31-9

Chemical Formula: C28H36O5S

Exact Mass: 484.2283

Molecular Weight: 484.65

Elemental Analysis: C, 69.39; H, 7.49; O, 16.51; S, 6.62

Price and Availability

Size Price Availability Quantity
5mg USD 450.00 2 Weeks
25mg USD 1,100.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Ro 41-5253; Ro 415253; Ro-41-5253.
IUPAC/Chemical Name
Benzoic acid, 4-(2-(7-(heptyloxy)-3,4-dihydro-4,4-dimethyl-2H-1-benzothiopyran-6-yl)-1-propenyl)-, S,S-dioxide, (E)-
InChi Key
JEIWQRITHXYGIF-LVZFUZTISA-N
InChi Code
InChI=1S/C28H36O5S/c1-5-6-7-8-9-15-33-25-19-26-24(28(3,4)14-16-34(26,31)32)18-23(25)20(2)17-21-10-12-22(13-11-21)27(29)30/h10-13,17-19H,5-9,14-16H2,1-4H3,(H,29,30)/b20-17+
SMILES Code
O=C(O)C1=CC=C(/C=C(C2=C(OCCCCCCC)C=C3C(C(C)(C)CCS3(=O)=O)=C2)\C)C=C1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 484.65 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Toma S, Isnardi L, Raffo P, Riccardi L, Dastoli G, Apfel C, LeMotte P, Bollag W. RARalpha antagonist Ro 41-5253 inhibits proliferation and induces apoptosis in breast-cancer cell lines. Int J Cancer. 1998 Sep 25;78(1):86-94. doi: 10.1002/(sici)1097-0215(19980925)78:1<86::aid-ijc14>3.0.co;2-3. PMID: 9724098. 2: Kasimanickam VR, Kasimanickam RK. Retinoic acid signaling biomarkers after treatment with retinoic acid and retinoic acid receptor alpha antagonist (Ro 41-5253) in canine testis: an in vitro organ culture study. Theriogenology. 2013 Jan 1;79(1):10-6. doi: 10.1016/j.theriogenology.2012.09.001. Epub 2012 Oct 25. PMID: 23102850. 3: Ke Q, Li R, Cai L, Wu SD, Li CM. Ro41-5253, a selective antagonist of retinoic acid receptor α, ameliorates chronic unpredictable mild stress-induced depressive-like behaviors in rats: Involvement of regulating HPA axis and improving hippocampal neuronal deficits. Brain Res Bull. 2019 Mar;146:302-309. doi: 10.1016/j.brainresbull.2019.01.022. Epub 2019 Jan 31. PMID: 30711623. 4: Schupp M, Curtin JC, Kim RJ, Billin AN, Lazar MA. A widely used retinoic acid receptor antagonist induces peroxisome proliferator-activated receptor-gamma activity. Mol Pharmacol. 2007 May;71(5):1251-7. doi: 10.1124/mol.106.033662. Epub 2007 Feb 8. PMID: 17290005. 5: Toma S, Raffo P, Isnardi L, Palumbo R. Retinoids in lung cancer chemoprevention and treatment. Ann Oncol. 1999;10 Suppl 5:S95-102. doi: 10.1093/annonc/10.suppl_5.s95. PMID: 10582149. 6: Bertram JS, Vine AL. Cancer prevention by retinoids and carotenoids: independent action on a common target. Biochim Biophys Acta. 2005 May 30;1740(2):170-8. doi: 10.1016/j.bbadis.2005.01.003. Epub 2005 Jan 25. PMID: 15949684. 7: Chen S, Yang Y, Xu J, Su L, Wang W. Effect of all-trans-retinoic acid on enterovirus 71 infection in vitro. Br J Nutr. 2014 May;111(9):1586-93. doi: 10.1017/S0007114513004133. Epub 2014 Feb 4. PMID: 24495389. 8: Zhang HL, Guo B, Yang ZQ, Duan CC, Geng S, Wang K, Yu HF, Yue ZP. ATRA Signaling Regulates the Expression of COL9A1 through BMP2-WNT4-RUNX1 Pathway in Antler Chondrocytes. J Exp Zool B Mol Dev Evol. 2017 Sep;328(6):575-586. doi: 10.1002/jez.b.22756. Epub 2017 Jun 22. PMID: 28643469. 9: Palmer JA, Smith AM, Egnash LA, Colwell MR, Donley ELR, Kirchner FR, Burrier RE. A human induced pluripotent stem cell-based in vitro assay predicts developmental toxicity through a retinoic acid receptor-mediated pathway for a series of related retinoid analogues. Reprod Toxicol. 2017 Oct;73:350-361. doi: 10.1016/j.reprotox.2017.07.011. Epub 2017 Jul 23. PMID: 28746836. 10: Lee HS, Kim SO, Ahn K, Park K. All-Trans Retinoic Acid Increases Aquaporin 3 Expression in Human Vaginal Epithelial Cells. Sex Med. 2016 Dec;4(4):e249-e254. doi: 10.1016/j.esxm.2016.07.001. Epub 2016 Jul 25. PMID: 27461974; PMCID: PMC5121539. 11: le Maire A, Teyssier C, Balaguer P, Bourguet W, Germain P. Regulation of RXR-RAR Heterodimers by RXR- and RAR-Specific Ligands and Their Combinations. Cells. 2019 Nov 5;8(11):1392. doi: 10.3390/cells8111392. PMID: 31694317; PMCID: PMC6912802. 12: Shi H, Yuan L, Yang H, Zang A. The mechanism of all-trans retinoic acid in the regulation of apelin expression in vascular endothelial cells. Biosci Rep. 2017 Dec 12;37(6):BSR20170684. doi: 10.1042/BSR20170684. PMID: 29070519; PMCID: PMC5725614. 13: Fontaine V, Boumedine T, Monteiro E, Fournié M, Gersende G, Sahel JA, Picaud S, Veillet S, Lafont R, Latil M, Dilda PJ, Camelo S. RAR Inhibitors Display Photo-Protective and Anti-Inflammatory Effects in A2E Stimulated RPE Cells In Vitro through Non-Specific Modulation of PPAR or RXR Transactivation. Int J Mol Sci. 2024 Mar 6;25(5):3037. doi: 10.3390/ijms25053037. PMID: 38474284; PMCID: PMC10932305. 14: Emionite L, Galmozzi F, Grattarola M, Boccardo F, Vergani L, Toma S. Histone deacetylase inhibitors enhance retinoid response in human breast cancer cell lines. Anticancer Res. 2004 Nov-Dec;24(6):4019-24. PMID: 15736447. 15: Toma S, Emionite L, Scaramuccia A, Ravera G, Scarabelli L. Retinoids and human breast cancer: in vivo effects of an antagonist for RAR-alpha. Cancer Lett. 2005 Feb 28;219(1):27-31. doi: 10.1016/j.canlet.2004.06.018. PMID: 15694661. 16: Emionite L, Galmozzi F, Raffo P, Vergani L, Toma S. Retinoids and malignant melanoma: a pathway of proliferation inhibition on SK MEL28 cell line. Anticancer Res. 2003 Jan-Feb;23(1A):13-9. PMID: 12680189. 17: Dawson HD, Collins G, Pyle R, Key M, Taub DD. The Retinoic Acid Receptor- alpha mediates human T-cell activation and Th2 cytokine and chemokine production. BMC Immunol. 2008 Apr 16;9:16. doi: 10.1186/1471-2172-9-16. PMID: 18416830; PMCID: PMC2394516. 18: Duprey-Díaz MV, Blagburn JM, Blanco RE. Exogenous Modulation of Retinoic Acid Signaling Affects Adult RGC Survival in the Frog Visual System after Optic Nerve Injury. PLoS One. 2016 Sep 9;11(9):e0162626. doi: 10.1371/journal.pone.0162626. PMID: 27611191; PMCID: PMC5017682. 19: Xiao Y, de Paiva CS, Yu Z, de Souza RG, Li DQ, Pflugfelder SC. Goblet cell- produced retinoic acid suppresses CD86 expression and IL-12 production in bone marrow-derived cells. Int Immunol. 2018 Sep 25;30(10):457-470. doi: 10.1093/intimm/dxy045. PMID: 30010888; PMCID: PMC6153729. 20: Vine AL, Bertram JS. Upregulation of connexin 43 by retinoids but not by non-provitamin A carotenoids requires RARs. Nutr Cancer. 2005;52(1):105-13. doi: 10.1207/s15327914nc5201_13. PMID: 16091010.